

# Effect of Detectable HIV-RNA at Baseline on the Response to Treatment With PegIFN and RBV in Patients Coinfected With HIV and HCV

Teresa Aldámiz-Echevarría<sup>1</sup>, Juan Berenguer<sup>1</sup>, Francisco Zamora<sup>2</sup>, Miguel von Wichmann<sup>3</sup>, Manel Crespo<sup>4</sup>, <sup>3</sup>, María Jesús Téllez<sup>5</sup>, Jose Sanz<sup>6</sup>, Herminia Esteban<sup>7</sup>, José María Bellón<sup>1</sup>, Juan González-García<sup>2</sup>, and the GESIDA 3603 and 5006 Study Groups

<sup>1</sup>Hosp. Gen. Univ. Gregorio Marañón~<sup>2</sup>Hosp. La Paz/IdiPAZ, <sup>3</sup>Hosp. de Donostia, <sup>4</sup>Hosp. Vall d'Hebron, ~<sup>5</sup>Hosp. Clínico San Carlos~ <sup>6</sup>Hosp. Príncipe de Asturias <sup>7</sup>Fundación SEIMC/GESIDA

Funding sources: Fundación para la Investigación y la Prevención del SIDA en España (FIPSE) (Refs. 36443/03, 36702/07, and 361020/10)



## RESULTS

### 1 Background and Aims

- Baseline predictors of sustained virologic response (SVR) after therapy with PegIFN and RBV (PR) in HIV/HCV+ patients include virus-related factors (e.g. HCV genotype and HCV-RNA), and host-related factors (e.g. liver fibrosis stage, and polymorphisms in *IL28B*).
- In one clinical trial of PR in coinfecting patients, detectable (vs. undetectable) HIV viral load (VL) at baseline was associated with an increased odds of SVR<sup>1</sup>
- We assessed whether HIV-VL that is detectable at baseline has an effect on treatment response to PR therapy.

<sup>1</sup> Chung et al. NEJM 2004).

### 3 Patients characteristics (I)

Characteristic	HIV-VL (-) cART	HIV-VL (-) No-cART	HIV-VL (+) cART	HIV-VL (+) No-cART	Total
Patients*	1183 (70)	62 (4)	288 (17)	149 (9)	1682
Male sex*	891 (76)	45 (74)	212 (74)	105 (70)	1253 (75)
Age - yr	41 (37 - 44)	39 (36 - 43)	40 (37 - 43)	39 (36 - 43)	40 (37 - 44)
History of IDU*	966 (82)	50 (81)	238 (83)	115 (77)	1369 (82)
CDC category C*	285 (25)	4 (7)	76 (27)	13 (9)	378 (23)
CD4 + cells nadir - n/mm <sup>3</sup> ‡	187 (100 - 283)	370 (265 - 500)	187 (96 - 287)	389 (262 - 500)	204 (110 - 308)
CD4 + cells baseline - n/mm <sup>3</sup> ‡	519 (391 - 725)	645 (478 - 1036)	475.5 (333 - 664)	520 (421 - 699)	515 (390 - 720)
HIV viral load - Log c/mL‡	-	-	2.37 (2.06 - 3.36)	3.84 (3.04 - 4.42)	-
Methadone use*	126 (12)	9 (16)	31 (12)	24 (17)	190 (12.5)
Type of cART*					
3-4 nRTI	142 (12)	NA	46 (16)	NA	188 (11)
2 nRTI + nnRTI	354 (30)	NA	105 (36)	NA	459 (27)
2 nRTI + PI	584 (49)	NA	105 (36)	NA	689 (41)
Other regimens	103 (9)	NA	32 (12)	NA	135 (8)

\*n (%); ‡median (IQR)

### 5 SVR by Genotypes

### 7 SVR Subgroup Analysis

### 9 Conclusions

- Detectable HIV-RNA at baseline was independently associated with a reduced likelihood of SVR.
- However, subgroup analysis adjusted by important baseline covariates indicated that this was only true in patients with detectable HIV-VL and cART.
- It remains to be determined whether these findings represents a true effect of HIV-VL on response to PR or a spurious association due to poor adherence to treatment.

### 2 Methods

- Pooled analysis of two large cohorts of HIV/HCV+ patients treated with PR in Spain between 2000 and 2008 (GESIDA 3603<sup>1</sup> and GESIDA 5006<sup>2</sup>).
- SVR was defined as an undetectable HCV RNA 24 weeks after discontinuation of PEG-IFN + RBV.
- Patients were categorized in 4 subgroups according to whether or nor were on cART and whether or not had detectable HIV-VL at the initiation of PEG-IFN + RBV
- Logistic regression models were used to test possible associations between SVR and pretreatment characteristics, including concomitant antiretroviral drugs.
- All analyses were performed on an ITT basis.

<sup>1</sup> Berenguer J, et al. Hepatology 2009; 50:407-413  
<sup>2</sup> González-García JJ, et al. 15th CROI, 2008; Paper #

### 4 Patients characteristics (II)

Characteristic	HIV-VL (-) cART	HIV-VL (-) No-cART	HIV-VL (+) cART	HIV-VL (+) No-cART	Total
Patients*	1183 (70)	62 (4)	288 (17)	149 (9)	1682
HCV genotype*					
1	598 (50)	25(40)	153 (53)	59 (39)	835 (50)
2	24 (2)	4 (6)	5 (2)	6 (4)	39 (2)
3	380 (32)	21 (34)	87 (30)	53 (35)	541 (32)
4	155 (13)	9 (14)	31 (11)	26 (17)	221 (13)
Unknown	26 (2)	3 (5)	12 (4)	5 (3)	46 (3)
HCV-RNA ≥ 500,000 IU/mL*	341 (30)	22 (40)	77 (28)	30 (21)	470 (30)
Liver Biopsy*	789 (67)	37(60)	212 (74)	104 (70)	1142 (68)
METAVIR F23*	317 (41)	11(30)	89 (42)	28 (27)	445 (40)
EtOH intake > 50 mg/d*	472 (40)	24 (39)	107 (37)	57 (38)	660 (39)
Type of IFN*					
Pegylated a2a	453 (38)	23 (37)	143 (49.6)	71 (48)	690 (41)
Pegylated a2b	730 (62)	39 (63)	145 (50.4)	78 (52)	992 (59)
RBV dose mg/kg/day‡	14 (12.6-15.6)	13 (11.8-15.3)	14 (12.3-15.3)	13.6 (12.3-15.3)	14 (12.6-15.3)

\*n (%); ‡median (IQR)

### 6 Baseline Predictors of SVR (Multivariate Logistic Regression Analysis)

### 8 Adjusted OR (95% CI) for SVR According to different categories

Adjusted by nadir CD4+ cell count, CDC clinical category, AZT use, HCV genotype, HCV-RNA, and liver fibrosis stage

### 8 The GESIDA 3603 Team

Principal Investigators	Study Coordinators	Statistician
J Berenguer, J Gonzalez	E Barquilla, H Esteban	JM Bellón

H. Gregorio Marañón, Madrid  
T Aldámiz, JM Bellón, J Cosin, I Gutiérrez, JC López, P Miralles, B Padilla, A Carrero, F Tejerina, C Diez, M Ramirez, M Sánchez-Conde, J Berenguer.

H. La Paz, Madrid  
J Alvarez, JR Arribas, I Bernardino, M Mora, F Pascual, JM Peña, E Rodriguez, I Valero, F Zamora, J González.

Fund SEIMC-GESIDA, Madrid  
E Aznar, E Barquilla, H Esteban, B Moyano

H. Príncipe Asturias, Madrid  
A Arranz, J de Miguel, J Sanz

H. Germans Trias i Pujol Badalona  
B Clotet, A Jou, C Tural

H. Ramón y Cajal, Madrid  
A Moreno, S Moreno, C Quereda, MA Sanfrutos

H. 12 de Octubre, Madrid  
MA Hernando, F Pulido, V Rodríguez, R Rubio

H. Getafe, Madrid  
G Gaspar, G Pérez

H. Santa Creu i Sant Pau Barcelona  
P Domingo, JM Guardiola

H. Clínica, Barcelona  
P Callau, JM Gatel, J Mallolas, JM Miro

H. Guadalajara, Guadalajara  
M Rodríguez, ML Montes

H. Severo Ochoa, Madrid  
M Cervero, JJ Jusdado, R Torre

H. Clínico Univ de Valencia, Valencia  
A Ferrer, MJ Galindo

H. La Fe, Valencia  
S Cuellar, J López-Aldeguer

H. Clínico San Carlos, Madrid  
MJ Téllez, J Vergas

H. La Princesa, Madrid  
I Santos, J Sanz

H. Vall d'Hebron, Barcelona  
M Crespo, E Van den Eynde

H. Donostia, San Sebastián  
J Arrizabalaga, JA Ibarren, MA Von Wichmann

H. Móstoles, Madrid  
C Barros, E Condés

H. General de Valencia, Valencia  
E Ortega, L Ortiz